Gloster H M, Harris K R, Roenigk R K
Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA.
J Am Acad Dermatol. 1996 Jul;35(1):82-7.
There is growing evidence that Mohs micrographic surgery (MMS) is the treatment of choice for dermatofibrosarcoma protuberans (DFSP).
This study retrospectively compared the recurrence rates of DFSP after MMS with those after wide surgical excision; results at the Mayo Clinic and in the world literature were evaluated. In addition, preoperative tumor sizes and postoperative defect sizes after MMS were compared to determine whether MMS conserved more normal tissue than wide surgical excision.
The medical records of 84 patients with DFSP who had been treated at the Mayo Clinic were reviewed. They were categorized into two treatment groups: MMS and surgical excision.
Fifteen patients with DFSP who underwent MMS had follow-up data available; one of these patients had local recurrence (recurrence rate, 6.6%; average duration of follow-up, 40 months). Thirty-nine patients had wide excision; four of these patients had local recurrences and one had pulmonary metastases (recurrence rate, 10%; average duration of follow-up, 36 months). A review of the world literature revealed neither local recurrences nor metastases in the 11 studies in which DFSP was treated with MMS. Overall, including our results, the average recurrence rate of DFSP after MMS was 0.6% (range, 0% to 6.6%) and the total recurrence rate was 1.6% (1 of 64). Including our series, DFSP was treated with wide excision in 15 studies; the average recurrence rate was 18% (range, 0% to 60%) and the total recurrence rate was 20% (100 of 489). In eight published studies, DFSP was surgically resected with undefined or conservative excisional margins; the average recurrence rate was 43% (range, 26% to 60%) and the total recurrence rate was 44% (140 of 317). A surgical margin of 2.5 cm to deep fascia was required for complete clearance of all tumors treated with MMS. Twenty-two percent of tumors were removed with a 0.5 cm margin, 50% with a 1.0 cm margin, 67% with a 1.5 cm margin, and 89% with a 2.0 cm margin.
On the basis of our results and data compiled from the literature, MMS may be the treatment of choice for DFSP because of its high cure rate and maximal conservation of tissue.
越来越多的证据表明,莫氏显微外科手术(MMS)是隆突性皮肤纤维肉瘤(DFSP)的首选治疗方法。
本研究回顾性比较了MMS治疗DFSP后的复发率与广泛手术切除后的复发率;评估了梅奥诊所及世界文献中的结果。此外,比较了MMS术前肿瘤大小和术后缺损大小,以确定MMS是否比广泛手术切除保留了更多的正常组织。
回顾了在梅奥诊所接受治疗的84例DFSP患者的病历。他们被分为两个治疗组:MMS组和手术切除组。
15例接受MMS治疗的DFSP患者有随访数据;其中1例患者出现局部复发(复发率为6.6%;平均随访时间为40个月)。39例患者接受了广泛切除;其中4例患者出现局部复发,1例出现肺转移(复发率为10%;平均随访时间为36个月)。对世界文献的回顾显示,在11项用MMS治疗DFSP的研究中,既没有局部复发也没有转移。总体而言,包括我们的结果,MMS治疗DFSP后的平均复发率为0.6%(范围为0%至6.6%),总复发率为1.6%(64例中的1例)。包括我们的系列研究在内,15项研究中对DFSP采用了广泛切除;平均复发率为18%(范围为0%至60%),总复发率为20%(489例中的100例)。在8项已发表的研究中,对DFSP进行了手术切除,切缘不明确或为保守切缘;平均复发率为43%(范围为26%至60%),总复发率为44%(317例中的140例)。用MMS治疗所有肿瘤,为完全清除肿瘤需要2.5 cm至深筋膜的手术切缘。22%的肿瘤切缘为0.5 cm,50%为1.0 cm,67%为1.5 cm,89%为2.0 cm。
根据我们的结果和文献汇总的数据,MMS可能是DFSP的首选治疗方法,因为其治愈率高且能最大程度地保留组织。